IL10 and systemic inflammatory response syndrome: Given that the levels of both IL-10 and IL-1β decrease under IETD-fmk treatment, we hypothesize that, unlike most conventional treatments, caspase-8 inhibition is able to counteract both phases of SIRS; pro- and anti-inflammatory.